NASDAQ:CTY City Therapeutics (CTY) Stock Price, News & Analysis $16.72 -0.26 (-1.53%) As of 10:50 AM Eastern Add Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartFDA EventsInsider TradesNews and TrendsSEC Filings About City Therapeutics Stock (NASDAQ:CTY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get City Therapeutics alerts:Sign Up Key Stats Today's Range$16.43▼$17.1750-Day Range N/A52-Week Range$15.81▼$23.88Volume17,586 shsAverage Volume276,567 shsMarket Capitalization$864.76 millionP/E RatioN/ADividend YieldN/APrice Target$37.33Consensus RatingBuy Company Overview City Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-related proteins. Its research focuses on designing RNAi therapies for potential use across a range of diseases. Launched in 2024, the company is developing technology intended to advance the design and delivery of RNAi medicines. Its work is research and development focused; the company’s activities center on building a therapeutic pipeline rather than marketing established products.AI Generated. May Contain Errors. Read More City Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreCTY MarketRank™: 4.278220451525 of 5 starsCity Therapeutics scored higher than 86% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingBuy Consensus RatingCity Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 2 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialCity Therapeutics has a consensus price target of $37.33, representing about 123.0% upside from its current price of $16.74.Amount of Analyst CoverageCity Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about City Therapeutics' stock forecast and price target. Earnings and Valuation0.7 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for City Therapeutics are expected to grow in the coming year, from ($6.35) to ($2.58) per share. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.59% of the float of City Therapeutics has been sold short.Short Interest Ratio / Days to CoverCity Therapeutics has a short interest ratio ("days to cover") of 2.27, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in City Therapeutics has recently increased by 100.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCity Therapeutics does not currently pay a dividend.Dividend GrowthCity Therapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.59 News SentimentCity Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of companies.News Coverage This WeekMarketBeat has tracked 11 news articles for City Therapeutics this week, compared to 4 articles on an average week.Search Interest4 people have searched for CTY on MarketBeat in the last 30 days. MarketBeat Follows3 people have added City Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of City Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $6,120,000.00 in company stock, which represents 0.7069% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, City Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,120,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsCity Therapeutics has minimal institutional ownership at this time.Read more about City Therapeutics' insider trading history. Receive CTY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for City Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTY Stock News HeadlinesThe Goldman Sachs Group Begins Coverage on City Therapeutics (NASDAQ:CTY)November 12, 2026 | americanbankingnews.comJefferies Financial Group Initiates Coverage on City Therapeutics (NASDAQ:CTY)November 12, 2026 | americanbankingnews.comYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.November 17 at 1:00 AM | Profits Run (Ad)Stifel Nicolaus Begins Coverage on City Therapeutics (NASDAQ:CTY)November 12, 2026 | americanbankingnews.comOppenheimer Initiates Coverage on City Therapeutics (NASDAQ:CTY)November 12, 2026 | americanbankingnews.comCity Therapeutics doses first participant in phase 1 trial of Stargardt disease treatment CITY-RBP4November 10, 2026 | msn.comCity Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt DiseaseNovember 10, 2026 | globenewswire.comCity Therapeutics (NASDAQ:CTY) Major Shareholder Purchases 170,000 Shares of StockOctober 20, 2026 | insidertrades.comSee More Headlines CTY Stock Analysis - Frequently Asked Questions How have CTY shares performed this year? City Therapeutics' stock was trading at $22.40 on October 16, 2026. Since then, CTY shares have decreased by 25.3% and is now trading at $16.74. When did City Therapeutics IPO? City Therapeutics (CTY) raised $200 million in an IPO on Friday, October 16th 2026. The company issued 11,111,111 shares at $17.00-$19.00 per share. When does the company's quiet period expire? City Therapeutics's quiet period expires on Wednesday, November 25th. City Therapeutics had issued 11,111,111 shares in its IPO on October 16th. The total size of the offering was $199,999,998 based on an initial share price of $18.00. During the company's quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company. How do I buy shares of City Therapeutics? Shares of CTY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today11/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:CTY CIK2143850 Webwww.citytx.com Phone(857) 357-2024FaxN/AEmployees75Year FoundedN/APrice Target and Rating Average Price Target for City Therapeutics$37.33 High Price Target$46.00 Low Price Target$32.00 Potential Upside/Downside+123.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares51,720,000Free FloatN/AMarket Cap$865.79 million OptionableN/A BetaN/A 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:CTY) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe $40 trillion number nobody won on Tuesday will touchDemocrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion ...Vault Metal | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding City Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share City Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.